ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma

We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Krakstad, Camilla, Tangen, Ingvild L., Hoivik, Erling A., Halle, Mari K., Berg, Anna, Werner, Henrica M., Ræder, Maria B., Kusonmano, Kanthida, Zou, June X., Øyan, Anne M., Stefansson, Ingunn, Trovik, Jone, Kalland, Karl-Henning, Chen, Hong-Wu, Salvesen, Helga B.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://ncbi.nlm.nih.gov/pubmed/26308378
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires